UPB (Upstream Bio) Accumulated other comprehensive income (loss) : $0.37 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Upstream Bio's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $0.37 Mil.

Upstream Bio's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 ($0.35 Mil) to Dec. 2024 ($-0.03 Mil) but then increased from Dec. 2024 ($-0.03 Mil) to Mar. 2025 ($0.37 Mil).

Upstream Bio's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.02 Mil) but then declined from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($-0.03 Mil).

Upstream Bio Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Upstream Bio's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Accumulated other comprehensive income (loss) Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

0.02

-0.03

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial			-	-0.06	0.35	-0.03	0.37

Upstream Bio Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Upstream Bio Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.